1.19
+5.31%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Palisade Bio
From its filings with the US Securities and Exchange Commission
Palisade Bio is based in Carlsbad, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PALI. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2024, it reported revenue of $0.
We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (“PDE4”) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Crohn’s disease (“CD”).
We are committed to advancing a next generation of once daily, oral PDE4 inhibitor prodrugs to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases.
We are developing a biomarker-based patient selection approach that we believe may aid clinicians in identifying patients who may better respond to PALI-2108, thereby improving the rate of clinical response previously demonstrated with PDE4 inhibitors. Our approach involves the use of clinical and multiomics data from large patient populations to identify PDE4-related biomarkers that are correlated with IBD, its severity, and which are modified with local PDE4-inhibitor therapy in the colon. Based on our research, we have initiated the development of corresponding biomarker assays for these PDE4-related biomarkers that we expect to use in our current and future clinical studies with the aim of developing regulatory approved tests for selecting potential responders to PALI-2108.
Quoted from its 10-K, filed 20 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Dec 2006
- Employees
- 14
- Website
- palisadebio.com ↗
- Head office
- 7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Donald WilliamsIndependent Chairman of the Board$114,717
- Mr. J. D. FinleyChief Executive Officer, Chief Financial Officer, Director, since 2021$813,000
- Dr. Mitchell JonesChief Medical Officer$581,000
- Dr. Emil ChuangIndependent Director
- Mr. Binxian WeiIndependent Director$61,235
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Palisade Bio develops oral therapies for gastrointestinal complications in the Health Care sector.
- The lead candidate LB1148 uses tranexamic acid to protect the intestinal barrier.
- The company employs 14 people in the US pharmaceutical industry.
Weaknesses
- The firm has only 12 full-time employees for its operations.
- Palisade Bio is headquartered in Carlsbad, California, limiting local talent pools.
- The company went public on 20 December 2006, facing long-term market pressures.
Opportunities
- LB1148 targets surgeries that risk disrupting the intestinal epithelial barrier significantly.
- Tranexamic acid is a well-characterized inhibitor suitable for oral liquid formulations.
- Polyethylene glycol and electrolytes enhance the aqueous solution for enteral administration.
Threats
- Damage to the intestinal barrier can cause broad acute and chronic conditions.
- Inflammation from enzyme leakage may complicate patient outcomes during surgical procedures.
- Post-operative digestive enzyme damage poses significant risks to tissue integrity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.